Faeth Therapeutics, Inc. Operating Lease, Payments
Faeth Therapeutics, Inc. (FTH) reported Operating Lease, Payments of $873.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-08-04
- Faeth Therapeutics, Inc. operating lease, payments for the quarter ending 2026-06-30 was $444.00K, a 5.46% increase year-over-year.
- Faeth Therapeutics, Inc. operating lease, payments for the quarter ending 2026-03-31 was $429.00K, a 9.87% decline year-over-year.
- Faeth Therapeutics, Inc. operating lease, payments for the quarter ending 2025-12-31 was $428.00K, a 9.89% decline year-over-year.
- Faeth Therapeutics, Inc. operating lease, payments for the quarter ending 2025-09-30 was $423.00K, a 10.19% decline year-over-year.
- Faeth Therapeutics, Inc. operating lease, payments for fiscal 2025 was $1.75M, a 6.77% decline from fiscal 2024.
- Faeth Therapeutics, Inc. operating lease, payments for fiscal 2024 was $1.88M, a 5.51% increase from fiscal 2023.
- Faeth Therapeutics, Inc. operating lease, payments for fiscal 2023 was $1.78M, a 12.11% increase from fiscal 2022.
- Faeth Therapeutics, Inc. operating lease, payments for fiscal 2022 was $1.58M.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $444.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $873.00K 10-Q · filed 2026-08-04 | $1.30M derived: sum of 3 quarters · filed 2026-08-04 | $1.72M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $429.00K 10-Q · filed 2026-05-15 | $857.00K derived: sum of 2 quarters · filed 2026-05-15 | $1.28M derived: sum of 3 quarters · filed 2026-05-15 | $1.70M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $428.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $851.00K derived: sum of 2 quarters · filed 2026-03-30 | $1.27M derived: sum of 3 quarters · filed 2026-08-04 | $1.75M 10-K · filed 2026-03-30 |
| 2025-09-30 | $423.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $844.00K derived: sum of 2 quarters · filed 2026-08-04 | $1.32M 10-Q · filed 2025-11-14 | $1.79M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $421.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $897.00K 10-Q · filed 2026-08-04 | $1.37M derived: sum of 3 quarters · filed 2026-08-04 | $1.84M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $476.00K 10-Q · filed 2026-05-15 | $951.00K derived: sum of 2 quarters · filed 2026-05-15 | $1.42M derived: sum of 3 quarters · filed 2026-05-15 | $1.89M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $475.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $946.00K derived: sum of 2 quarters · filed 2026-03-30 | $1.41M derived: sum of 3 quarters · filed 2026-03-30 | $1.88M 10-K · filed 2026-03-30 |
| 2024-09-30 | $471.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $938.00K derived: sum of 2 quarters · filed 2025-11-14 | $1.40M 10-Q · filed 2025-11-14 | $1.86M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $467.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $929.00K 10-Q · filed 2025-08-05 | $1.39M derived: sum of 3 quarters · filed 2025-08-05 | $1.82M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $462.00K 10-Q · filed 2025-05-06 | $919.00K derived: sum of 2 quarters · filed 2025-05-06 | $1.35M derived: sum of 3 quarters · filed 2025-05-06 | $1.83M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $457.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $891.00K derived: sum of 2 quarters · filed 2025-03-28 | $1.37M derived: sum of 3 quarters · filed 2025-03-28 | $1.78M 10-K · filed 2025-03-28 |
| 2023-09-30 | $434.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $910.00K derived: sum of 2 quarters · filed 2023-11-07 | $1.32M 10-Q · filed 2023-11-07 | $1.72M derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | $476.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $886.00K 10-Q · filed 2023-08-03 | $1.28M derived: sum of 3 quarters · filed 2023-08-03 | $1.68M derived: sum of 4 quarters · filed 2023-08-03 |
| 2023-03-31 | $410.00K 10-Q · filed 2023-05-09 | $809.00K derived: sum of 2 quarters · filed 2023-05-09 | $1.21M derived: sum of 3 quarters · filed 2023-05-09 | $1.60M derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-12-31 | $399.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $798.00K derived: sum of 2 quarters · filed 2023-03-29 | $1.19M derived: sum of 3 quarters · filed 2023-03-29 | $1.58M 10-K · filed 2023-03-29 |
| 2022-09-30 | $399.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $794.00K derived: sum of 2 quarters · filed 2022-11-08 | $1.19M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $395.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $787.00K 10-Q · filed 2022-08-09 | ||
| 2022-03-31 | $392.00K 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |